{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:57:25Z","timestamp":1778284645150,"version":"3.51.4"},"reference-count":54,"publisher":"Impact Journals, LLC","issue":"50","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,12,13]]},"DOI":"10.18632\/oncotarget.12856","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T18:56:18Z","timestamp":1477335378000},"page":"82567-82579","source":"Crossref","is-referenced-by-count":17,"title":["Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis"],"prefix":"10.18632","volume":"7","author":[{"given":"Chuanjun","family":"Zhuo","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, Wenzhou Seventh People's Hospital, Wenzhou, Zhejiang, 325005, China"},{"name":"Department of Psychological Medicine, Jining Medical University, Jining, Shandong, 272067, China"},{"name":"Department of Psychological Medicine, Tianjin Anding Hospital, Tianjin, 300222, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xubin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Tianjin Cancer Institute and Hospital, Tianjin, 30000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqing","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Tianjin Cancer Institute and Hospital, Tianjin, 30000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunli","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Tianjin Medical University General Hospital, Tianjin, 300075, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailong","family":"Cui","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Tianjin Medical University General Hospital, Tianjin, 300075, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Chinese PLA (People's Liberation Army) General Hospital; Chinese PLA (People's Liberation Army) Medical School, Beijing, 100853, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Jining Medical University, Jining, Shandong, 272067, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Tao","sequence":"additional","affiliation":[{"name":"Beijing Shijian Integrated Medicine Science Institute, Beijing, 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Wenzhou Seventh People's Hospital, Wenzhou, Zhejiang, 325005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Forman","year":"2011","journal-title":"Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12885-015-1431-6","article-title":"BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)","volume":"15","author":"Davis","year":"2015","journal-title":"BMC cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00345-009-0502-1","article-title":"Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study","volume":"28","author":"Kumon","year":"2010","journal-title":"World J Urol"},{"key":"4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"European Association of U. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Roupret","year":"2013","journal-title":"Eur Urol"},{"key":"5","first-page":"3422","article-title":"Pilot study of intravesical instillation of two new generation anthracycline antibiotics in prevention of superficial bladder cancer recurrence","volume":"123","author":"Zhang","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Del Prete","year":"2010","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1464-410X.2008.07968.x","article-title":"Risk-adapted use of intravesical immunotherapy","volume":"102","author":"O'Donnell","year":"2008","journal-title":"BJU Int"},{"key":"8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0960-7404(02)00008-7","article-title":"BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer","volume":"11","author":"Bassi","year":"2002","journal-title":"Surg Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2007.08.015","article-title":"Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur Urol"},{"key":"10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Witjes","year":"2008","journal-title":"Eur Urol"},{"key":"11","first-page":"CD006885","article-title":"Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer","author":"Tian","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1586\/14737140.4.6.1057","article-title":"Advances in intravesical therapy of urinary bladder cancer","volume":"4","author":"Malmstrom","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"13","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1464-410X.2005.05739.x","article-title":"Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option","volume":"96","author":"Frea","year":"2005","journal-title":"BJU Int"},{"key":"14","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1517\/14656566.8.18.3265","article-title":"Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer","volume":"8","author":"Blackhall","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"15","first-page":"2013","article-title":"[Assessment of efficacy of arterial infusion chemotherapy with gemcitabine for four cases of advanced pancreatic cancer]","volume":"34","author":"Muranaka","year":"2007","journal-title":"Gan to kagaku ryoho"},{"key":"16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CAD.0b013e328010ef47","article-title":"Gemcitabine-induced apoptosis in 5637 cell line: anmodel for high-risk superficial bladder cancer","volume":"18","author":"Agliano","year":"2007","journal-title":"Anti-cancer drugs"},{"key":"17","first-page":"676","article-title":"Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials","volume":"53","author":"Adcock","year":"2000","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/cncr.10496","article-title":"Randomized study of single early instillation of (2\u201dR)-4\u2032-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma","volume":"94","author":"Ohshima","year":"2002","journal-title":"Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00345-009-0390-4","article-title":"Topic issue on new treatments in bladder cancer","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"key":"20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","article-title":"Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial","volume":"67","author":"Rodriguez-Molina","year":"2015","journal-title":"Eur Urol"},{"key":"21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Schiavina","year":"2013","journal-title":"J Urol"},{"key":"22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365599.2012.694906","article-title":"Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Gu\u00e9rin instillation therapy of patients with carcinomaof the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up","volume":"46","author":"Rintala","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer","volume":"108","author":"Tanaka","year":"2011","journal-title":"BJU Int"},{"key":"24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","article-title":"Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Gu\u00e9rin and with Bacillus Calmette-Gu\u00e9rin alone in patients with carcinomaof the urinary bladder: Results of an EORTC genito-urinary group randomized phase 2 trial (30993)","volume":"59","author":"Bono","year":"2011","journal-title":"Eur Urol"},{"key":"25","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Autorino","year":"2010","journal-title":"Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study","volume":"84","author":"Costantini","year":"2010","journal-title":"Urol Int"},{"key":"27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"de Reijke","year":"2010","journal-title":"Eur Urol"},{"key":"28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.juro.2008.03.038","article-title":"Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled Study","volume":"180","author":"Bartoletti","year":"2008","journal-title":"J Urol"},{"key":"29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-Term Intravesical Adjuvant Chemotherapy Further Reduces Recurrence Rate Compared with Short-Term Intravesical Chemotherapy and Short-Term Therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in Patients with Non-Muscle-Invasive Bladder Carcinoma","volume":"52","author":"Huland","year":"2007","journal-title":"Eur Urol"},{"key":"30","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13. 5 mg) versus Mitomycin C","volume":"52","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2007","journal-title":"Eur Urol"},{"key":"31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1442-2042.2005.01064.x","article-title":"Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer","volume":"12","author":"Li","year":"2005","journal-title":"Int J Urol"},{"key":"32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinomaof the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906)","volume":"173","author":"Carpentier","year":"2005","journal-title":"J Urol"},{"key":"33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C, BCG instillations versus BCG alone in treatment of carcinomaof the urinary bladder: A Nordic study","volume":"43","author":"Rintala","year":"2003","journal-title":"Eur Urol"},{"key":"34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Vespasiani","year":"2003","journal-title":"J Urol"},{"key":"35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","article-title":"Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial","volume":"166","author":"Sylvester","year":"2001","journal-title":"J Urol"},{"key":"36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1442-2042.2000.00176.x","article-title":"Clinical experience with BCG alone versus BCG plus epirubicin","volume":"7","author":"Kendi","year":"2000","journal-title":"Int J Urol"},{"key":"37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-5347(05)68555-2","article-title":"Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: A randomized prospective study","volume":"162","author":"Ghoneim","year":"1999","journal-title":"J Urol"},{"key":"38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","article-title":"Long-term follow-up of an eortc randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer","volume":"52","author":"Oosterlinck","year":"1998","journal-title":"Urology"},{"key":"39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF02550957","article-title":"BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes","volume":"28","author":"Barbalias","year":"1996","journal-title":"Int Urol Nephrol"},{"key":"40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(01)65936-6","article-title":"Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer","volume":"156","author":"Rajala","year":"1996","journal-title":"J Urol"},{"key":"41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study","volume":"1","author":"Barton Grossman","year":"1995","journal-title":"Urol Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","article-title":"5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guerin with epirubicin and interferon-alpha2b in patients with T1 bladder cancer","volume":"191","author":"Malmstrom","year":"2014","journal-title":"J Urol"},{"key":"43","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Lamm","year":"2002","journal-title":"J Urol"},{"key":"44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Witjes","year":"2009","journal-title":"Eur Urol"},{"key":"45","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","article-title":"Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial","volume":"67","author":"Rodriguez-Molina","year":"2015","journal-title":"Eur Urol"},{"key":"46","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Astobieta","year":"2009","journal-title":"J Urol"},{"key":"47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Oosterlinck","year":"2014","journal-title":"Eur Urol"},{"key":"48","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(01)65405-3","article-title":"Significance of serum free prostate specific antigen in the screening of prostate cancer","volume":"156","author":"Tomaru","year":"1996","journal-title":"J Urol"},{"key":"49","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bock","year":"2004","journal-title":"Urology"},{"key":"50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1986.4.3.425","article-title":"Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue","volume":"4","author":"Hong","year":"1986","journal-title":"J Clin Oncol"},{"key":"51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0302-2838(03)00140-4","article-title":"Alternating mitomycin C, BCG instillations versus BCG alone in treatment of carcinomaof the urinary bladder: a nordic study","volume":"43","author":"Rintala","year":"2003","journal-title":"Eur Urol"},{"key":"52","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","article-title":"Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinomaof the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993)","volume":"59","author":"Bono","year":"2011","journal-title":"Eur Urol"},{"key":"53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/14737140.2016.1143777","article-title":"The safety and efficacy of gemcitabine for the treatment of bladder cancer","volume":"16","author":"Krabbe","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"54","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13. 5 mg) versus mitomycin C","volume":"52","author":"Martinez-Pineiro","year":"2007","journal-title":"Eur Urol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T13:46:23Z","timestamp":1596721583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":54,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2016,12,13]]}},"alternative-id":["12856","27788495"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12856","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]}}}